Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

Similar articles for PubMed (Select 23092832)

1.

Meta-analysis of the efficacy of amifostine in the prevention of cisplatin ototoxicity.

Duval M, Daniel SJ.

J Otolaryngol Head Neck Surg. 2012 Oct;41(5):309-15. Review.

PMID:
23092832
2.
3.

[Amifostine otoprotection to cisplatin ototoxicity: a guinea pig study using otoacoustic emission distortion products (DPOEA) and scanning electron microscopy].

Hyppolito MA, de Oliveira AA, Lessa RM, Rossato M.

Braz J Otorhinolaryngol. 2005 May-Jun;71(3):268-73. Epub 2005 Dec 14. Portuguese.

4.

Amifostine for children with medulloblastoma treated with cisplatin-based chemotherapy.

Fisher MJ, Lange BJ, Needle MN, Janss AJ, Shu HK, Adamson PC, Phillips PC.

Pediatr Blood Cancer. 2004 Dec;43(7):780-4.

PMID:
15390300
5.

Interventions for preventing neuropathy caused by cisplatin and related compounds.

Albers J, Chaudhry V, Cavaletti G, Donehower R.

Cochrane Database Syst Rev. 2007 Jan 24;(1):CD005228. Review. Update in: Cochrane Database Syst Rev. 2011;(2):CD005228.

PMID:
17253547
6.

Assessment of the protective effects of amifostine against cisplatin-induced toxicity.

Hussain AE, Blakley BW, Nicolas M, Balderston J.

J Otolaryngol. 2003 Oct;32(5):294-7.

PMID:
14974858
7.

Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative Group.

Planting AS, Catimel G, de Mulder PH, de Graeff A, Höppener F, Verweij J, Oster W, Vermorken JB.

Ann Oncol. 1999 Jun;10(6):693-700.

8.

A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).

Gradishar WJ, Stephenson P, Glover DJ, Neuberg DS, Moore MR, Windschitl HE, Piel I, Abeloff MD.

Cancer. 2001 Nov 15;92(10):2517-22.

PMID:
11745184
9.

Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis.

Sasse AD, Clark LG, Sasse EC, Clark OA.

Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):784-91. Epub 2005 Sep 29. Review.

PMID:
16198504
10.

Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study.

Marina N, Chang KW, Malogolowkin M, London WB, Frazier AL, Womer RB, Rescorla F, Billmire DF, Davis MM, Perlman EJ, Giller R, Lauer SJ, Olson TA; Children's Oncology Group.

Cancer. 2005 Aug 15;104(4):841-7.

11.
12.

The potential of amifostine: from cytoprotectant to therapeutic agent.

Santini V, Giles FJ.

Haematologica. 1999 Nov;84(11):1035-42. Review.

13.

Transtympanic Ringer's lactate application in the prevention of cisplatinum-induced ototoxicity in a chinchilla animal model.

Munguia R, Sahmkow SI, Funnell WR, Daniel SJ.

Otolaryngol Head Neck Surg. 2010 Jul;143(1):134-40. doi: 10.1016/j.otohns.2010.02.007. Epub 2010 May 8.

PMID:
20620632
14.

High-dose Cisplatin with amifostine: ototoxicity and pharmacokinetics.

Ekborn A, Hansson J, Ehrsson H, Eksborg S, Wallin I, Wagenius G, Laurell G.

Laryngoscope. 2004 Sep;114(9):1660-7.

PMID:
15475801
15.

Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial.

Komaki R, Lee JS, Milas L, Lee HK, Fossella FV, Herbst RS, Allen PK, Liao Z, Stevens CW, Lu C, Zinner RG, Papadimitrakopoulou VA, Kies MS, Blumenschein GR Jr, Pisters KM, Glisson BS, Kurie J, Kaplan B, Garza VP, Mooring D, Tucker SL, Cox JD.

Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1369-77.

PMID:
15050312
16.

Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma.

Gurney JG, Bass JK, Onar-Thomas A, Huang J, Chintagumpala M, Bouffet E, Hassall T, Gururangan S, Heath JA, Kellie S, Cohn R, Fisher MJ, Panandiker AP, Merchant TE, Srinivasan A, Wetmore C, Qaddoumi I, Stewart CF, Armstrong GT, Broniscer A, Gajjar A.

Neuro Oncol. 2014 Jun;16(6):848-55. doi: 10.1093/neuonc/not241. Epub 2014 Jan 10.

17.

Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin.

Gallegos-Castorena S, Martínez-Avalos A, Mohar-Betancourt A, Guerrero-Avendaño G, Zapata-Tarrés M, Medina-Sansón A.

Pediatr Hematol Oncol. 2007 Sep;24(6):403-8.

PMID:
17710657
18.

Administration of the cytoprotectant amifostine.

Lindemann K.

Clin J Oncol Nurs. 1998 Jul;2(3):101-4.

PMID:
10232150
19.

Ototoxicity: bioprotective mechanisms.

Rybak LP, Kelly T.

Curr Opin Otolaryngol Head Neck Surg. 2003 Oct;11(5):328-33. Review.

PMID:
14502062
20.

American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.

Hensley ML, Schuchter LM, Lindley C, Meropol NJ, Cohen GI, Broder G, Gradishar WJ, Green DM, Langdon RJ Jr, Mitchell RB, Negrin R, Szatrowski TP, Thigpen JT, Von Hoff D, Wasserman TH, Winer EP, Pfister DG.

J Clin Oncol. 1999 Oct;17(10):3333-55.

PMID:
10506637
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk